Flexible sigmoidoscopy screening helps reduce colorectal cancer incidence and mortality over long term; Study
Written By : Hina Zahid
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2021-11-10 03:30 GMT | Update On 2021-11-10 03:49 GMT
Advertisement
Recent reports showed that the protective effect of flexible sigmoidoscopy (FS) screening was maintained up to17 years, although differences were reported by sex.
A single flexible sigmoidoscopy screening at age 55 to 64 years represents a safe and effective strategy associated with a substantial reduction in colorectal cancer (CRC) incidence and mortality, confirms a randomized controlled trial.
The strong protective effect was maintained up to 15 years and 19 years, respectively. The findings of the study have been published in Annals of Internal Medicine.
Large, randomized trials of flexible sigmoidoscopy screening had shown a substantial reduction in CRC incidence (range, 18% to 26%) and mortality (range, 22% to 31%) after a median follow-up of 10 to 12 years in the intention-to-treat analysis. The recent reports of the extended incidence and mortality follow-up from three of those trials showed that the screening effect was maintained up to 15 to 17 years. Additional data about the duration of the protection conferred by a single sigmoidoscopy screening and about differences of screening effect by sex and age could offer useful insight to support evidence-based recommendations about screening intervals as well as about alternative strategies aimed to achieve a larger protective effect.
Researchers from University Hospital Città della Salute e della Scienza, Turin, Italy, randomly assigned 34,272 persons aged 55 to 64 at 6 centers in Italy to receive either a once-only flexible sigmoidoscopy screening or usual care (control group). Compared to the control group, colorectal cancer incidence was 19% lower at 15 years and CRC mortality was 22% lower 19 at years, respectively, after a single screening sigmoidoscopy. Consistent with previous estimates on the basis of the 11-year follow-up, more than 80% of averted deaths are attributable to the prevention of incident CRC via adenoma removal at screening. These findings confirm the strong preventive effect of flexible sigmoidoscopy screening.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.